INZYbenzinga

Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 10, 2025 by benzinga